OUTLOOK THERAPEUTICS, INC.

Inactive Instrument

Analyst Reco. OUTLOOK THERAPEUTICS, INC. Nasdaq

Equities

US69012T1079

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

BTIG Upgrades Outlook Therapeutics to Buy From Neutral, Price Target at $50	Mar. 27	MT
Chardan Upgrades Outlook Therapeutics to Buy From Neutral, $3 Price Target; Says Risk/Reward is Favorable for Lytenava BLA Resubmission	Feb. 15	MT
Chardan Upgrades Outlook Therapeutics to Buy From Neutral, $3 Price Target	Feb. 15	MT
Guggenheim Upgrades Outlook Therapeutics to Buy From Neutral, Sets Price Target at $2	Jan. 25	MT
Brookline Capital Upgrades Outlook Therapeutics to Buy From Hold, Price Target is $1.57	Jan. 25	MT
Capital One Upgrades Outlook Therapeutics to Overweight From Equalweight With $5 Price Target	Dec. 27	MT
Chardan Downgrades Outlook Therapeutics to Neutral From Buy	23-08-31	MT
HC Wainwright Downgrades Outlook Therapeutics to Neutral From Buy, Price Target is $1	23-08-31	MT
Brookline Capital Downgrades Outlook Therapeutics to Hold From Buy	23-08-30	MT
Cantor Fitzgerald Downgrades Outlook Therapeutics to Neutral From Overweight, Adjusts Price Target to $1 From $4.50	23-08-30	MT
BTIG Downgrades Outlook Therapeutics to Neutral From Buy	23-08-30	MT
Capital One Initiates Outlook Therapeutics With Overweight Rating, $5 Price Target	23-07-13	MT
Guggenheim Initiates Outlook Therapeutics at Buy With $5 Price Target	23-04-03	MT
Cantor Fitzgerald Initiates Outlook Therapeutics at Overweight With $4 Price Target	23-02-06	MT
HC Wainwright Adjusts Price Target on Outlook Therapeutics to $5 From $6, Maintains Buy Rating	23-01-06	MT
BTIG Starts Outlook Therapeutics at Buy With $7 Price Target	22-10-31	MT
Chardan Capital Starts Outlook Therapeutics at Buy With $10 Price Target	22-09-13	MT
Ascendiant Capital Adjusts Price Target on Outlook Therapeutics to $7.25 From $7, Maintains Buy Rating	21-12-27	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Like the pros, access all the transcripts and spot the best opportunities before anyone else.

Unlock them now!

fermer